Dupixent in post-burn pruritus
Full IRB Study Title:
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
IRB Study ID: 2024-002
The purpose of this study is to investigate if the study drug, Dupixent, is effective in improving the symptoms post-burn itchy skin (called pruritis). Additionally, the safety of Dupixent and how well it is tolerated at different doses will be evaluated.
For complete study details, please view this study on ClinicalTrials.gov
Study Sponsor:
Akron Children's Hospital
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
JoAnn Katz, (330) 543-0690
Who May Qualify:
Persons 18-60 years old with post-burn hypertrophic scars of any size which required grafting or epidermal autografting for an acute burn injury, with continued complaint of pruritus due to inadequate relief from standard of care (medical management by antihistamine and neuroleptic medications) after at least four weeks and are a minimum of four weeks after their last grafting surgery, and who speak English sufficient to participate in the study.
Who Does NOT Qualify:
- Patients currently taking Dupixent for any other diagnosis
- Patients with a known allergy to Dupixent
- Pregnant and or lactating mothers
- Anyone treated for pruritus using laser therapy
- Patients currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications
- Patients currently taking steroids
- Persons with developmental delays or otherwise unable to complete measures
- Prisoners or anyone otherwise unable to give their own consent or who is not their own guardian
- Patients with one or more of the following existing disorders:
- conjunctivitis
- co-existing dermatological condition except burns
- Any type of cancer
- Patients requiring dialysis
- Chronic Stage 3 or higher kidney disease
- Biliary disorder
- Gall bladder disorder or another renal or hepatic disorder which, in the opinion of study physician, deems this study inappropriate for an eligible individual.
Lead Investigator
Anjay Khandelwal, MD, FACS, FICS, FABA
Director, Adult and Pediatric Burn Institute; Acute/Reconstructive Burn Surgeon; Surgical Critical Care; Director, Pediatric and Adult Cosmetic & Reconstructive Laser Program; The Marci M. Matthews Endowed Chair for Excellence in Burn Care; Program Director, Acute and Reconstructive Burn Fellowship
Adult and Pediatric Burn Institute
